
Opinion|Videos|October 28, 2023
Considerations and Challenges Surrounding CAR-T Therapy and Bispecifics
Expert oncologists offer considerations for the use of CAR-T therapy and bispecific antibodies in follicular lymphoma and discuss potential challenges that may limit the use of these agents in clinical practice.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
EMA’s Review of Daraxonrasib in PDAC Accelerated Under Phased Review Process
2
Orca-T Improves Chronic GVHD-Free Survival in Hematologic Cancers
3
TIP12 Validation of a Multimodal Artificial Intelligence Prognostic Model in Early-Stage HR+/HER2− Breast Cancer
4
Five Gastrointestinal Cancer Abstracts You May Have Missed at ESMO GI 2026
5






![“[Epcoritamab/R2] is a good option for [patients] at first relapse or even further, even if they are very high risk,” said Benoit Tessoulin, MD, PhD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d4c175d2fd9b443716f5ad06bfae7bc796a1795a-1200x1200.jpg?w=350&fit=crop&auto=format)




























































